Abstract
Fibroblast growth factors (FGFs) are involved in numerous metabolic processes. The endocrine subfamily of FGFs, consisting of FGF19, FGF21, and FGF23, might have beneficial effects in the treatment of diabetes mellitus (DM) and/or obesity. The analog with the greatest potential, FGF21, lowers blood glucose levels, improves insulin sensitivity, and induces weight loss in several animal models. In this review we summarize recent (pre)clinical findings with FGF21 analogs in animal models and men. Furthermore, possible applications of FGF21 analogs for pets with DM will be discussed. As currently, information about the use of FGF21 analogs in pet animals is scarce.
Original language | English |
---|---|
Article number | 1086987 |
Pages (from-to) | 1-8 |
Number of pages | 8 |
Journal | Frontiers in Veterinary Science |
Volume | 9 |
Early online date | 2022 |
DOIs | |
Publication status | Published - 9 Jan 2023 |
Bibliographical note
Publisher Copyright:Copyright © 2023 Corbee, van Everdingen, Kooistra and Penning.
Keywords
- FGF
- diabetes
- endocrine
- glucose
- insulin
- metabolism
- obesity